Clinical Trials Logo

IGA Nephropathy clinical trials

View clinical trials related to IGA Nephropathy.

Filter by:

NCT ID: NCT05016323 Recruiting - IgA Nephropathy Clinical Trials

A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.

Start date: September 9, 2021
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of HR19042 capsules compared to matching placebo for the treatment of primary IgA nephropathy, and explore the optimal dose for the treatment.

NCT ID: NCT04905212 Terminated - IgA Nephropathy Clinical Trials

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

Start date: November 4, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical study with an optional open label extension to evaluate the safety and efficacy of Telitacicept for Injection (RC18) in the treatment of IgA nephropathy.

NCT ID: NCT04858724 Recruiting - IgA Nephropathy Clinical Trials

The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)

Start date: December 1, 2020
Phase:
Study type: Observational [Patient Registry]

1. Establish an IgAN cohort collaboration group and expert committee to carry out registration research. 2. Construct IgAN structured data set standards, formulate structured data collection templates of diagnosis and treatment , and establish multi-center data integration systems on this basis. 3. Establish a standardized IgAN database for combined Hospital Information System and the big data platform of the Medical Federation. 4. Develop IgAN database managements and open standards for data sharing, and carry out high-quality clinical or basic research.

NCT ID: NCT04833374 Recruiting - IgA Nephropathy Clinical Trials

Steroids Therapy in IgA Nephropathy With Crescents

Start date: May 24, 2021
Phase: Phase 3
Study type: Interventional

This prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of steroids therapy for patients of IgA nephropathy with crescents.

NCT ID: NCT04805047 Recruiting - IgA Nephropathy Clinical Trials

SodiUm Restriction by Behavioral Intervention

SURBI
Start date: May 15, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the effects and efficacy of dietary sodium restriction by mean of a new healthcare approach in patients with immunoglobulin A nephropathy. The test persons in the intervention group are actively supported to adhere to a restricted sodium diet with a structured education program in combination with regular sodium excretion monitoring.

NCT ID: NCT04716231 Recruiting - IgA Nephropathy Clinical Trials

Atacicept in Subjects With IgA Nephropathy

ORIGIN 3
Start date: May 23, 2023
Phase: Phase 3
Study type: Interventional

A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

NCT ID: NCT04684745 Recruiting - IgA Nephropathy Clinical Trials

Open-Label Extension Study of BION-1301 in IgA Nephropathy

Start date: September 10, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label extension (OLE) study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of BION-1301 in adults with IgA nephropathy

NCT ID: NCT04578834 Active, not recruiting - IgA Nephropathy Clinical Trials

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

APPLAUSE-IgAN
Start date: January 25, 2021
Phase: Phase 3
Study type: Interventional

The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

NCT ID: NCT04573920 Active, not recruiting - Clinical trials for Diabetic Kidney Disease

Atrasentan in Patients With Proteinuric Glomerular Diseases

AFFINITY
Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

NCT ID: NCT04573478 Active, not recruiting - IgA Nephropathy Clinical Trials

Atrasentan in Patients With IgA Nephropathy

ALIGN
Start date: December 11, 2020
Phase: Phase 3
Study type: Interventional

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.